FT-003
Sponsors
Frontera Therapeutics
Conditions
Diabetic Macular EdemaNeovascular Age-related Macular Degeneration
Phase 1
Gene Therapy for Wet AMD
Not yet recruitingNCT05611424
Start: 2023-05-01End: 2027-12-30Target: 18Updated: 2023-04-26
Gene Therapy for Diabetic Macular Edema
RecruitingNCT05916391
Start: 2023-05-19End: 2028-05-01Target: 18Updated: 2023-06-23
Gene Therapy(FT-003) for Wet AMD
RecruitingNCT06492863
Start: 2023-08-15End: 2028-10-15Target: 78Updated: 2024-07-09
Gene Therapy for DME
RecruitingNCT06492876
Start: 2023-11-15End: 2028-11-15Target: 78Updated: 2024-07-09